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Abstract 
The blood-brain barrier (BBB) is a protective entholelial barrier lining the brain microvasculature which 
prevents brain delivery of the majority of therapies against brain diseases. Hence, there is an urgent 
need to develop vehicles which efficiently penetrate the BBB to deliver therapies into the brain. The 
drug L-DOPA efficiently and specifically crosses the BBB via the large amino acid transporter (LAT)-
1 protein to enter the brain. Thus, we synthesized L-DOPA-functionalized multi-branched nanoflower-
like gold nanoparticles (L-DOPA-AuNF) using a seed-mediated method involving catechols as a direct 
reducing-cum-capping agent, and examined their ability to cross the BBB to act as brain-penetrating 
nano-vehicles. We show L-DOPA-AuNF efficiently penetrate the BBB compared to similarly sized and 
shaped AuNFs functionalized with a non-targeting ligand. Furthermore, we show L-DOPA-AuNF are 
efficiently internalized by brain macrophages without inducing inflammation. These results 
demonstrate the application of L-DOPA-AuNF as a non-inflammatory brain-specific nano-vehicle to 
efficiently deliver therapies into the brain. 
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Background 
Development of therapies and diagnostics (theranostics) against brain disorders such as ParkinsonÕs 
disease (PD) is hampered by the inability of macromolecules to enter the brain due to the protective 
blood-brain barrier (BBB)1, a highly impermeable endothelial layer lining the brain microvasculature. 
Hence, the successful development of vehicles capable of penetrating the BBB will significantly 
increase the number of clinically viable theranostics to combat brain diseases.  
Gold nanoparticles (AuNP) are an attractive platform to deliver theranostics into the brain as they are 
highly biocompatible and their surfaces are easily modified with various functional groups, allowing 
for a wide range of brain-targeting and cargo-delivery strategies to be employed2. Furthermore, AuNP 
can be imaged in vivo using non-invasive X-ray computed tomography (CT)3, without the need for 
additional chemical labelling procedures.  
Although AuNP functionalised with transferrin4,5 glucose6, and insulin7 have demonstrated BBB 
penetration, lack of brain specificity remains an issue which may lead to unwanted side-effects in 
peripheral organs. Hence, a more specific targeting ligand is required to resolve such inadequacies for 
effective clinical translation.  
Functionalizing AuNP with the drug L-DOPA is an attractive, yet unexploited, strategy for specific 
brain delivery. L-DOPA is an FDA-approved drug employed in the clinic against PD which is actively 
transported across the BBB by the large neutral amino acid transporter-1 (LAT-1) into the brain to 
replace dopamine. Hence, its ability to penetrate the BBB in an efficient, safe and non-toxic manner is 
well established. Importantly, LAT-1 is highly expressed at the BBB compared to peripheral non-barrier 
tissues8, enabling enhanced brain penetration. Furthermore, the binding affinity of L-DOPA to LAT-1 
is relatively high (Km 150-200 µM)
9, allowing L-DOPA/LAT-1 interaction to occur even for 
nanoparticles with low ligand densities, resulting in high levels of nanoparticle capture.  
Previously, we have demonstrated the use of catechols including L-DOPA, D-DOPA, dopamine, and 
4-ethylcatechol as efficient reducing-cum-capping agents for the seed mediated synthesis of 
monodisperse nanoflower-like gold nanoparticles (AuNF) to target breast cancer cells10. The catechol 
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functional group of L-DOPA efficiently reduces Au3+ to Au0 on the surface of gold seeds and eventually 
adsorbs on the surface of the AuNFs to present the primary α-amino and α-carboxyl groups necessary 
for interaction with LAT-1. As such, this synthetic procedure affords a simple and cost-effective means 
of obtaining multi-branched, catechol-functionalized AuNF without the need for lengthy and costly 
conjugations with targeting peptides, antibodies, or aptamers. Additionally, multi-branched AuNFs are 
a more attractive brain-penetrating nano-vehicle platform than spherical AuNPs as they have a larger 
surface area available for drug loading and can be easily tuned to absorb near infrared (NIR) light for 
photothermal therapy and bioimaging10.  
In the present study, we expanded our previous work to examine whether multi-branched AuNF 
functionalized with the LAT-1-targeting ligands L-DOPA or its chiral isomer D-DOPA, which is 
recognized by LAT-1 along with other D-isomer amino-acids 11-13, safely and efficiently penetrate the 
BBB compared to similarly shaped and sized AuNFs functionalized with non-targeting control ligands 
(4-ethyl catechol or dopamine) in order to lay the foundations for the application of L-DOPA-
functionalized AuNF as a brain-specific nano-vehicle for brain imaging and theranostics delivery in the 
clinic. The ability of AuNF to enter the brain was examined on an in vitro model of the human BBB 
employing the immortalized human brain endothelial cell line hCMEC/D314 and validated using 
primary brain endothelial monolayers isolated from adult rat brains. In addition, AuNF uptake by brain 
macrophages (microglia cells) was characterized to examine AuNF clearance and inflammation 
induction following brain penetration to further establish their safe application as vehicles for 
theranostics against brain diseases.  
 
Methods 
Unless otherwise stated, all materials were supplied by Sigma-Aldrich (U.K.). 
AuNF synthesis and characterization 
Synthesis: AuNF were synthesized using a seed-mediated method as previously described10. Briefly, 
spherical gold seeds (14 nm) were prepared by reducing gold chloride with sodium citrate using the 
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Turkevich method. To obtain L-DOPA-functionalized AuNF, 100µL of 0.1M HAuCl4·3H2O and 400µL 
of 10mg/mL of mPEG thiol were added to an aqueous dispersion of spherical gold seeds, followed by 
the addition of 4.0mL of 15mM L-DOPA solution under vigorous stirring at room temperature (RT). 
The synthesized AuNF were purified by centrifugation and rinsing with Milli-Q water to obtain a dark-
blue colloidal dispersion. AuNF were functionalized with the LAT-1 targeting ligands L-DOPA (L-
DOPA-AuNF) or D-DOPA (D-DOPA-AuNF). Non-targeting controls with similar size, morphology 
and z-potential were prepared by functionalizing AuNF with 4-ethylcatechol (4-EC-AuNF) or 
dopamine (DA-AuNF), as described in our previous publication10. Both 4-EC and DA lack the 
necessary amino-carboxyl moiety required for LAT-1 recognition15. 
Characterization: Full characterization of the synthesized AuNFs has been described in our previous 
publication10. Briefly, AuNFs were characterized by bright-field high-resolution transmission electron 
microscopy (TEM) using a JEOL JEM-2100F operated at 200kV, and UV-vis-NIR spectrophotometry 
(Agilent Cary 6000i). Hydrodynamic diameter and zeta-potential were characterized through dynamic 
light scattering (DLS) employing a Zetasizer Nano (Malvern Instrument Ltd). Elemental gold 
concentration of AuNF was determined using inductively coupled plasma-atomic emission 
spectroscopy (ICP-AES; ThermoScientific iCAP 6300 Duo). The successful surface functionalization 
of the AuNF with catechols was confirmed using X-ray photoelectron spectrophotometry (XPS; 
Thermo Scientific K-Alpha+ X-ray Photoelectron Spectrophotometer).  
Cell culture 
Human brain endothelial cells: The immortalized human brain endothelial cell line hCMEC/D3 was 
obtained from Dr. Romero, Open University, U.K. hCMEC/D3 were established by lentiviral vector 
transduction of endothelial cells derived from human temporal lobe microvessels with human 
telomerase (hTERT) and SV40 large T antigen16. hCMEC/D3 form tight, polarized monolayers with 
low paracellular flux and expression of transporters closely mimicking the in vivo condition17-19. 
hCMEC/D3 were cultured in Cell-Bind culture flasks (Corning, UK) in EBM-2 medium (Lonza, 
Switzerland) supplemented with vascular endothelial growth factor (VEGF) (unless otherwise stated), 
insulin-like growth factor-1 (IGF1), epidermal growth factor (EGF), basic fibroblast growth factor 
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(bFGF), hydrocortisone, ascorbic acid, gentamycin, and 2.5% (v/v) foetal calf serum (FCS) (hereafter 
termed full EBM). Cells were incubated at 37oC in 5% CO2, and passaged by detachment with 
trypsin/EDTA. Cells were employed between passages 25-35.  
Primary rat brain microvascular endothelial cells (1oEC): All procedures were carried out in 
accordance with the Animals (Scientific Procedures) Act, 1986. Brain microvascular endothelial cells 
were extracted from adult male Wistar rats (150g, Charles River, UK) employing a BSA-density 
centrifugation isolation method20. Briefly, rats were sacrificed (CO2 exposure and cervical dislocation) 
and the brain cortex isolated over ice-cold dissection buffer (HBSS with 1%BSA and 2% 
penicillin/streptomycin).  Following removal of the sub-cortical myelin, meninges and all visible blood 
vessels, the brains were homogenized in ice-cold dissection buffer followed by incubation in digestion 
buffer (DMEM/HamÕs F12 with collagenase, dispase, DNase type I and trypsin) at 37oC. The brain 
digest solution was mixed with separation gradient buffer (25% BSA) and centrifuged. The microvessel 
pellet was incubated in digestion buffer (1hr at 37oC), followed by centrifugation and plating in 
culturing medium (full EBM with 4µg/mL puromycin and 100µg/mL endothelial cell growth 
supplement) employing Cell-BIND T75 cell culture flasks (Corning, USA) coated with calf skin 
collagen type-I (100µg/mL) and bovine plasma fibronectin (10µg/mL). After 5 days, the culture 
medium was changed to low puromycin (1µg/mL) until reaching confluency. The brain endothelial 
cells were then trypsinized (trypsin/EDTA) and aliquoted in freezing medium (DMEM with 10 % FCS, 
10% DMSO) to create frozen stocks. For experiments, cells were defrosted, expanded in full EBM as 
above and plated in appropriate plastic-ware. Isolated primary rat brain endothelial cells formed a highly 
pure, homogenous monolayer with minimal intercellular gaps as evidenced by even cellular distribution 
with extensive cell-to-cell contact, formation of alignment patterns and lack of contaminating cells (fig. 
S1a). In addition, the monolayers adopted a BBB phenotype, as demonstrated by intercellular 
expression of the tight-junction proteins zona occludens-1 (fig. S1b) and occludin (fig. S1c), and low 
paracellular permeability (fig. S1d) comparable to previously published data21,22.  
Endothelial cell plating: For translocation experiments, cells were grown on polyester Transwell filters 
(3.0µm pore diameter, 0.33cm2 surface area, Millipore, UK) coated with collagen/fibronectin in full 
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EBM. Once cells reached ~90% confluence, medium was changed to EBM without VEGF (hereafter 
termed NV-EMB), and cultured for a further 3 days. For experiments not requiring transwells, cells 
were plated directly onto collagen/fibronectin-coated 12 well-plates (for AuNF quantification, see 
below) or glass cover-slips (for AuNF visualization, see below) and grown as above. 
Microglial cells: Microglia experiments were carried out on the immortalized mouse microglia N9 cell 
line23, which reliably replicates primary microglia with respect to NO production, cytokine synthesis 
and expression of cell surface markers24-26. N9 microglia were cultured in DulbeccoÕs Modified EagleÕs 
Medium (DMEM) with 5% FCS, 8mM L-glutamine and 50U/mL penicillin and 50µg/mL streptomycin 
(full DMEM). 
Microglial cells were plated in 12-well plates (AuNF quantification, see below), or onto glass coverslips 
in 24-well plates (AuNF visualization, see below) and incubated for 24hr before experimentation began. 
Cell treatment: AuNF treatments were carried out at 10 µg/mL for all nanoparticle functionalizations. 
At the designated time-point, medium was collected and cells thoroughly washed with HBSS to remove 
non-internalized AuNF. For AuNF internalization quantification, cells were collected through 
trypsinization (endothelial cells) or scraping (microglia) and the cell pellet digested in aqua regia (see 
below). For visualization of AuNF internalization by confocal or light-transmission microscopy, cells 
were washed as above before fixation with 4% PFa.  Fixed cells were washed and stored at 4 oC before 
staining (see below).  
For transcytosis experiments, AuNF were administered into the apical chamber.  The basal chamber 
medium was then directly collected for digestion (see below) following a 6hr, 24hr or 48hr incubation. 
A 48hr time-point was adopted to minimize the hindrance of the transwell filter to AuNF translocation 
(fig. S2). Monolayer permeability was assessed through quantification of paracellular transport of 
FITC-dextran (4 kDa or 70 kDa) by quantifying fluorescence intensity in the basal medium (490 em/525 
ex, Promega GloMax plate reader). Permeability coefficient was calculated by correcting for 4kDa 
FITC-dextran transport across empty transwell filters as previously described19.  
AuNF quantification 
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AuNF content was measured by quantifying gold concentration through either ICP-AES or ICP-MS. 
Cells or culture medium were digested with aqua regia (HCl:HNO3 at 3:1) overnight and neutralized 
with MilliQ water before ICP-AES gold quantification. Ion counts were converted to gold mass with a 
gold solution standard curve. In order to control for unintended differences in the initial AuNF treatment 
dose, a sample of the AuNF treatment solution was analysed in parallel and the AuNF quantity in the 
samples expressed as a percentage of the initial dose.  
Confocal microscopy 
Intracellular AuNF were imaged with a laser scanning Leica SP5 confocal microscope employing an 
argon 546nm laser on reflectance mode. To visualize the location of endothelial cells (in confluent 
monolayers), nuclei were stained with DAPI and the DAPI signalled overlaid on the reflectance image. 
Given that microglia did not form a monolayer, their cell bodies were in addition stained with an anti-
b-actin antibody to delineate their cell bodies. In order to corroborate the intracellular localization of 
AuNF, Z-stack series were created to visualize AuNF at different levels within the cells.  
Western blotting 
LAT-1 expression was verified through immunostaining of Western blots (WB) from hCMEC/D3, 
1oEC, and N9 cell lysates. Cells were lysed with RIPA buffer with 10% protein inhibitors.  Proteins 
were resolved by SDS-PAGE (10% gel) and transferred to PVDF membranes. Membranes were stained 
with anti-LAT1 (ThermoFisher Scientific, UK) and horse radish peroxidase (HRP)-anti-goat secondary 
antibody. Immunodetection was visualized through enhanced chemiluminescence (ThermoFisher 
Scientific, UK).  
Griess assay 
The Griess assay indirectly quantifies the amount of nitric oxide detecting its stable metabolite, nitrite27. 
Following treatment of microglia with AuNF or lipopolysaccharide (LPS), Griess reagent was mixed 
with cell culture medium in a 1:1 ratio and color development monitored by measuring optical density 
(OD) at 540nm (GloMax plate reader, Promega). The OD measurement was converted to concentration 
of nitrite with a sodium nitrite standard curve.  
 8 
Cytotoxicity assays  
Cytotoxicity was assessed by an MTS assay (Promega, U.K.) or an LDH release assay (Promega, U.K.). 
MTS assays were carried out by incubating cells with MTS reagent followed by quantification of OD 
at 490nm. Viability was determined as a percentage of the OD from control cells.  
LDH assays were carried out by mixing cell culture medium with LDH assay reagent and LDH 
concentration (released LDH) quantified through OD measurement at 490 nm. Cells were then lysed in 
the original medium and the new LDH concentration in the culture medium (total LDH) quantified as 
before. Cytotoxicity was assessed by changes in the released LDH: total LDH ratio and expressed either 
as an absolute ratio or percentage of control treatment.  
High resolution (HR)-TEM preparation and imaging 
Primary brain endothelial cell monolayers grown on transwell filters were prepared for HR-TEM 
imaging following AuNF treatment. Monolayers were washed with 0.9% saline and fixed with 4% 
glutaraldehyde with 0.1% hydrogen peroxide in 0.1M HEPES buffer. Following replacement of 
glutaraldehyde with pure 0.1M HEPES buffer, monolayers were osmium stained by immersing in 1% 
OsO4 (in 0.1M HEPES with 1.5% potassium ferricyanide, 1.5% calcium chloride) at RT. Following 
thorough washing with distilled water, the samples were serially dehydrated in ethanol (70%, 95%, 
100%) and acetonitrile (100%). The transwell supports were then embedded in resin (35.2% Quetol, 
45.5% NSA, 19.4% MNA v/v%) by serially immersing in resin:acetonitrile solution (50:50, 75:25, 
100:0, 24hrs/step). The samples were then immersed in 100% resin with BDMA under vacuum and 
incubated at 60oC for 24hrs. Once embedded, 70-100nm TEM sections were cut using a diamond knife 
(Diatome, Austria) on an ultramicrotome (Ultracut Reichert, Austria) and collected on copper grids. 
Cells were imaged using bright field TEM conditions on an FEI Titan 80-300 (Thermo Fisher Scientific, 
Oregon, USA) operated at 300kV. 
Statistics 
Results are expressed as mean+SEM of n=3, unless stated otherwise. Lines of best fit were calculated 
through linear regression analysis using GraphPad Prism 4.0 (GraphPad, USA). Statistics were 
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performed using GraphPad Prism 4.0. Statistically significant differences (p<0.05) were identified by 
StudentÕs t-test (between two groups) or one-way analysis of variance (ANOVA) with TukeyÕs post-
hoc (three or more groups).  
 
Results 
Functionalization of AuNF with L- or D-DOPA ligands reduces their accumulation within brain 
endothelial monolayers  
To examine whether L/D-DOPA functionalization promotes AuNF internalization into brain 
endothelial cells, hCMEC/D3 human brain endothelial monolayers were treated with AuNF 
functionalized with the LAT-1-targeting ligands L-DOPA or D-DOPA, or the non-targeting ligands, 4-
ethylcatechol (4-EC-AuNF) or dopamine (DA-AuNF). As reported previously10, all functionalized 
AuNFs were approximately 90nm in diameter (by TEM) with similar surface charge, and possessed 
homogenous nano-flower morphology and monodispersity, hence enabling a valid comparison of 
biological effects. A time-course study was first carried out by treating the hCMEC/D3 monolayers 
with each type of functionalized AuNF for 4hr, 8hr, 12hr and 24hr. hCMEC/D3 monolayers steadily 
internalized 4-EC- and DA-AuNF throughout the 24hr time-course, with an average internalization rate 
of 2.75% and 2.72% of the initial dose (%ID)/hr, respectively (fig. 1a), reaching a maximum 
internalization amount of 60.4 + 3.2 and 62.8 + 4.7 %ID, respectively, at 24hr (fig. 1b). The increase in 
4-EC- and DA-AuNF internalization by the hCMEC/D3 monolayer was accompanied by a decrease of 
non-internalized 4-EC- and DA-AuNF remaining in the culture medium after a 24hr incubation (3.3 + 
0.4 and 4.5 + 0.6 %ID, respectively) (fig. 1c). Interestingly, cellular internalization of L-DOPA- and D-
DOPA-AuNF was significantly lower than the 4-EC/DA-AuNF, with an internalization rate of 0.22 and 
0.56 %ID/hr, respectively (fig. 1a), reaching a maximum internalization amount of 5.9 + 1.1 and 13.0 
+ 2.2 %ID, respectively, at 24hr (fig. 1b). Importantly, the low amount of internalization of the L- and 
D-DOPA-AuNF was accompanied by an elevated level of AuNF remaining in the cell culture medium 
(89.0 + 1.8 and 77.7 + 2.4 %ID, respectively) (fig. 1c), indicating that the low intracellular reading was 
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not due to either lack of available nanomaterial in the medium or loss of intracellular nanomaterial 
during the collection process (the lack of 100%ID recovery level, however could be due to AuNF 
remaining bound to the culture plate or lost during the thorough washing steps). In order to examine 
whether the AuNF internalization pattern was specific for the immortalized hCMEC/D3 cell line, 
primary rat brain endothelial monolayers (1oEC) were also treated with 4-EC-, DA- or L-DOPA-AuNF. 
Similar to the hCMEC/D3 monolayers, the internalization rates into 1oEC monolayers were comparable 
between the 4-EC- and DA-AuNF (1.7 and 1.8 %ID/hr, respectively). Furthermore, the pattern of higher 
internalization compared to L-DOPA-AuNF (0.7 %ID/hr), was maintained (fig. 1d). At 24hr, the 4-EC- 
and DA-AuNF had comparably high levels of internalization (40.2 + 1.9 and 45.3 + 5 %ID, 
respectively), and the lowest amount of internalisation was measured for the L-DOPA-AuNF (20.9 + 
0.5 %ID), (fig. 1e). 
To verify that the AuNF associated with the hCMEC/D3 monolayers were internalized into the cells, 
and not simply strongly adhered to the cell membrane, the intracellular localization of the AuNFs was 
determined through confocal reflectance microscopy. Z-stacks spanning 4.2-7.6µm (comprising the 
majority of the cell height) were created for untreated and AuNF treated (4-EC- and L-DOPA-AuNF) 
cell monolayers (fig. 2). Although the L-DOPA-AuNF treated monolayers had a negligible AuNF signal 
comparable to the untreated monolayers, numerous 4-EC-AuNF inclusions were detected spanning the 
entire Z-stack, indicating 4-EC-AuNFs were present throughout the intracellular space, confirming 
cellular internalization. In addition, the AuNF localization was either restricted to the cytoplasm or 
lining the peri-nuclear space, with no significant penetration into the nucleus (fig. S3).  
To confirm that the L-DOPA-AuNF endothelial accumulation was due to an energy-dependent, 
endocytic mechanism, monolayers were treated under energy-depleting conditions (4oC). Incubating 
hCMEC/D3 monolayers (fig. S4a) or 1oEC monolayers (fig. S4b) at 4oC led to a significant reduction 
in L-DOPA-AuNF internalization compared to incubation at 37oC (0.7 + 0.3 vs. 2.4 + 0.3 %ID, 
hCMEC/D3; -0.2 + 0.2 vs. 4.7 + 0.5 %ID, 1oEC), indicating requirement of an energy-dependent 
endocytic process for L-DOPA-AuNF internalization in both cell types.  
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Functionalization of AuNF with L- or D-DOPA ligands increases their transport across brain 
endothelial monolayers  
Given that cellular uptake does not necessarily correlate with BBB penetration4, we hypothesized the 
high uptake of non-targeted AuNF may be due to intracellular sequestration, while the L/D-DOPA-
functionalized AuNF may be more efficiently exocytosed as a mechanism for BBB transportation. To 
test this hypothesis, endothelial monolayers plated on transwell supports were treated with AuNF for 
48hr and gold content in the basal chamber quantified through ICP-AES. A significantly greater amount 
of L-DOPA-AuNF was measured in the basolateral medium compared to the 4-EC-AuNF in both 
hCMEC/D3 monolayers (25.5 + 3.0 vs. 16.9 + 0.99 %ID) (fig. 3a) and primary rat brain endothelial 
monolayers (58.6 + 7.4 vs. 35.6 + 1.1 %ID) (fig. 3b). Importantly, treatment with either L-DOPA- or 
4-EC-AuNF did not induce cytotoxicity (fig. S5a) or increase permeability of either the hCMEC/D3 
monolayers (fig. S5b) or the 1oEC monolayers (fig. S5c), indicating the increase in basolateral AuNF 
concentration was not due to a breakdown in monolayer integrity following AuNF treatment.  
To confirm transport of L-DOPA-AuNF through the BBB, interaction of L-DOPA-AuNF with 1oEC 
monolayers was visualized through HR-TEM (fig. 3c). L-DOPA-AuNF were observed in three stages 
of translocation: 1) in close contact with the apical cell membrane without internalization (top panel, 
dashed arrow); 2) properly internalized into the intracellular space (bottom panel, arrow); 3) released 
into the basolateral space (bottom panel, arrow head), confirming transcellular transport of the L-
DOPA-AuNF.  
The transport of AuNF across peripheral endothelial monolayers was examined by treating human 
umbilical vein endothelial cell monolayers with L-DOPA- or 4-EC-AuNF for 6hr (fig. S6a) or 24hrs 
(fig. S6b) and quantifying basal gold through ICP-MS. Similarly to rat brain endothelial monolayers, 
transport of L-DOPA-AuNF across human umbilical vein endothelial cell monolayers was higher 
compared to 4-EC-AuNF at both time-points. Furthermore, the rate of transport for 4-EC- and L-DOPA-
AuNF was comparable to that seen in brain endothelial monolayers (0.74 and 1.15%ID/hr, 
respectively). The involvement of direct transport across the LAT-1 channel pore was examined by 
addition of increasing concentrations of the LAT-1 competitive substrate 3-iodo-L-tyrosine. 
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Interestingly, no effect on AuNF transport was seen for either functionalization scheme at either 6hr 
(fig. S6c) or 24 hr (fig. S6d). Importantly, the permeability of the endothelial monolayer was not 
affected (24hrs) by either AuNF treatment or 3-iodo-L-tyrosine co-treatment (fig. S6d).  
 
Brain macrophages (microglia) efficiently internalize AuNF functionalized with L- or D-DOPA ligands 
without induction of inflammation  
Brain macrophages (microglia) are the main cell type responsible for clearance of foreign entities, and 
capture and process exogenous nanomaterials28, 29. Therefore, to examine the capacity of AuNF to be 
cleared from the brain following BBB penetration, internalization of AuNF into microglia was 
quantified. Interestingly, a 24hr treatment with AuNF led to a reversed pattern of internalization 
compared to internalization into endothelial monolayers, with a higher intracellular concentration for 
the L-DOPA- and D-DOPA-AuNF (37.9 + 2.3 and 41.9 + 5.9 %ID) compared to the 4-EC- and DA-
AuNF (fig. 4a). Importantly, the amount of AuNF internalization was inversely proportional to the 
amount of non-internalized AuNF remaining in the culture medium (fig. 4b). This pattern of 
internalization was also evident at 8hr post-treatment (fig. S7a,b). Furthermore, L-DOPA-AuNF 
internalization was significantly inhibited by incubation at 4oC, indicating an energy-dependent process 
(fig. 4c). While there was no effect of low temperature incubation on internalization of 4-EC-AuNF 
(fig. 4c), this effect could be due to the short incubation time (4hr) and low internalization rate, or an 
energy independent process mediated by the AuNF morphology. In order to determine whether AuNF 
internalization induced inflammation, microglia cells were treated with L-DOPA- or DA-AuNF for 
24hr, followed by quantification of nitric oxide (NO) production. Neither AuNF increased NO 
production comparted to non-treated cells (fig. 4d). In contrast, treatment with LPS induced a marked 
increase in NO production, demonstrating the ability of the cells to become inflamed (fig. 5d).  
Light transmission microscopy and confocal reflectance microscopy analysis of microglia cells treated 
with 4-EC- or L-DOPA-AuNF echoed the ICP-AES results, with comparably low AuNF detection 
levels under light microscopy between untreated and 4-EC-AuNF treated cells (fig. 5 a,b), and a 
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marginally increased gold detection level in 4-EC-AuNF treated cells compared to untreated cells under 
confocal reflectance microscopy (fig. 5 d, e). Conversely, a significantly stronger AuNF detection signal 
for the L-DOPA-AuNF treated cells was seen under both light microscopy (fig. 5c) and confocal 
reflectance microscopy (fig. 5f). Z-stack analysis revealed L-DOPA-AuNF could be detected 
throughout the cell (fig. S8), indicating proper cellular internalization. In addition, the Z-stack analysis 
revealed AuNF internalization was restricted to the cytoplasmic space surrounding the nucleus similarly 
to endothelial cells.  
Expression of LAT-1 was confirmed through Western blot (fig. S9). A specific protein band of 55kDa, 
corresponding to the molecular weight of LAT-1, was detected for all three cell types, demonstrating 
positive LAT-1 expression, as has been shown for macrophages and brain endothelial cells30-32. 
 
Discussion  
Our results demonstrate that AuNF functionalization with L-DOPA or D-DOPA ligands leads to 
significantly higher AuNF transportation across an in vitro BBB model formed by a hCMEC/D3 
monolayer. Interestingly, efficient BBB transcytosis occurred with minimal cellular accumulation, 
suggesting efficient endothelial escape. In contrast, AuNFs functionalized with the non-targeting 
control ligand, 4-EC, had lower rates of BBB transcytosis but significantly higher cellular accumulation, 
indicating sequestration by the endothelial cells. Importantly, the uptake and transport trend in 
immortalized human brain endothelial cells was maintained in experiments employing isolated primary 
rat brain endothelial cells, excluding the possibility of an experimental artefact due to the 
immortalization process. In addition, confocal reflectance imaging and transmission electron 
microscopy studies, coupled with the low-temperature inhibition assays, demonstrated that the majority 
of cell-associated AuNF were internalized in an energy-dependent process. Crucially, the amount of L-
DOPA-AuNFs transported across the BBB (1.22%ID/hr) is higher than what has been reported in the 
literature for in vitro BBB models (0.1-1%ID/hr)5, 33-35. Furthermore, the transportation rate of AuNF 
across the BBB monolayer was comparable to that seen in monolayers composed of peripheral human 
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umbilical vein endothelial cells, indicating L-DOPA-AuNF are indeed able to overcome the 
impermeability of the BBB. Hence, functionalization of AuNF with L-DOPA confers a significantly 
improved strategy for the highly efficient shuttling of nanoparticles into the brain.  
Significantly, a reversed trend of AuNP uptake was seen in microglia cells, with the highest 
accumulation occurring for the L-DOPA/D-DOPA functionalized AuNF. Again, light microscopy and 
confocal reflectance microscopy, coupled with uptake assays at low temperature, indicated L-DOPA-
AuNF uptake was indeed intracellular. The discrepancy in AuNF uptake between cell types may be due 
to differences in membrane dynamics governing the endocytosis of the target receptor (presumably 
LAT-1) in each phenotype. Cellular internalization of free L-DOPA through the LAT-1 channel pore 
occurs independently of LAT-1 endocytosis36, 37. However, as the size of the AuNF used in this study 
is significantly larger than the size of the LAT-1 transporter38, AuNF uptake must occur through an 
alternative, endocytosis-dependent mechanism, possibly driven through target protein clustering at the 
cell membrane due to the multi-valent L-DOPA functionalization of AuNF, as has been shown for 
multimeric antibodies inducing clustering and internalization of membrane proteins on endothelial 
cells39. In support of this hypothesis, co-treatment with 3-iodo-L-tyrosine, a competitive ligand for 
direct transport across the LAT-1 channel pore, did not affect the transport of L-DOPA-AuNF across 
endothelial monolayers. Hence, LAT-1 membrane clustering in brain endothelial cells might lead to an 
association with guiding proteins responsible for transport of the AuNF across the monolayer, resulting 
in exocytosis at the basolateral membrane. Conversely, in macrophages, which have been shown to 
express LAT-130,31 but do not form monolayers, the internalization mechanism might not be equipped 
with signals to promote cargo transcytosis, leading to capture of the AuNF within the cell body. 
However, as microglia are phagocytic cells, a receptor independent internalization mechanism may also 
significantly contribute to AuNF capture.  
In addition to cellular phenotype, the geometry of the AuNF may also modulate the uptake of the 
nanomaterials into brain endothelial cells. In a study on the uptake of negatively charged, hydrophilic, 
polyethylene glycol (PEG)-NPs of varying aspect-ratios, it was reported that epithelial cells 
preferentially internalized disk-shaped PEG-NPs compared to rod-like and smaller disk-like PEG 
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NPs40. Hence, it is possible that the spikes of the present AuNF modulate cell interaction to induce 
endocytic entry across the plasma membrane of the brain endothelial cells. The spikes of the AuNFs 
may also be able to translocate across the plasma membrane of the brain endothelial cells, which may 
promote subsequent transport of the AuNFs across the BBB: the TEM images in figure 4 show very 
intimate contact between the spikes of the AuNF and are suggestive of this process. Indeed, such a 
mechanism has been proposed previously to facilitate transport of high aspect-ratio carbon nanotubes 
across brain endothelial cells41. Future work will deconvolute the effects of geometry and surface 
functionalisation on cellular internalization.  
 Importantly, the present work shows that even though L-DOPA-AuNF are highly internalized by 
microglial cells, this does not induce microglial activation, indicating detrimental brain inflammation 
will not occur following L-DOPA-AuNF brain entry. In addition, given that microglia are able to 
internalize nanomaterials without inducing overt inflammation29, the present work indicates L-DOPA-
AuNF will be promptly and safely cleared from the extracellular space following brain delivery of their 
pay-load, further supporting the safe application of these nanoparticles as brain-delivery nano-vehicles 
vehicles in the clinic. Furthermore, confocal microscopy indicated that internalized AuNF remained in 
the cytoplasmic area or lined the nuclear barrier without causing damage to the nucleus. This 
observation further underlines the biosafety of the present AuNF-based nano-vehicle formulation, as 
previous studies have shown that treatment with gold nanoparticles of similar size leads to nuclear 
localization and cytoxicity42.  
In conclusion, we show that the L-DOPA-functionalized AuNFs are efficiently transported across well-
established in vitro BBB models in a ligand-dependent manner and are readily taken up by brain 
macrophages with no obvious inflammatory effects. These findings lay the foundations for a gold 
theranostic nano-vehicle with significantly higher access to the brain than previously possible, and with 
minimal cytotoxicity and inflammatory responses in the brain following payload delivery.  
 
Abbreviations 
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L/D-DOPA, L/D-3,4-dihydroxyphenyalanine; DA, dopamine; 4-EC, 4-ethyl-catecholamine; BBB, 
blood-brain barrier; AuNF, gold nanoflower; LAT-1, large neutral amino acid transporter-1; 
hCMEC/D3, human cerebral microvascular endothelial cell/D3 clone 
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Figure legends 
Figure 1. Internalization of gold nanoflowers (AuNF) into hCMEC/D3 or primary brain 
endothelial cell (1oEC) monolayers. hCMEC/D3 or 1oEC monolayers were treated with 10µg/mL 
AuNF functionalized with either 4-ethylcatechol (4-EC), dopamine (DA), L-DOPA or D-DOPA. AuNF 
internalization rate in hCMEC/D3 (a) or 1oEC (d) was calculated by quantifying cell-associated gold 
through ICP-AES at 4, 8, 12 and 24hr following treatment. The total amount of internalized AuNF into 
hCMEC/D3 (b) or 1oEC (e), as well as AuNF remaining in the culture medium of hCMEC/D3 (c), 
following a 24hr incubation was similarly measured. AuNF quantity was calculated as a percentage of 
the initial dose (%ID). Results are displayed as mean+SEM of at least three independent experiments. 
*,*** denote p<0.05 and 0.001, respectively vs. 4-EC. ##,### denote p<0.005, 0.001, respectively vs. 
DA. Statistical significance was determined by a one-way ANOVA with TukeyÕs post-hoc test.  
 
Figure 2. Confocal reflectance microscopy Z-stack imaging of intracellular gold nanoflowers 
(AuNF) in hCMEC/D3 human endothelial monolayers. AuNF internalization into hCMEC/D3 
monolayers following a 24hr treatment (10µg/mL) was visualized through confocal reflectance 
microscopy employing an argon 546 nm laser. The intracellular distribution of AuNF was visualized 
by constructing Z-stacks (of 4.2µm or 7.6µm depth) for untreated cells (top panels) or cells treated with 
4-EC-AuNF (middle panels) or L-DOPA-AuNF (bottom panels). Laser power, exposure and gain 
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parameters were kept constant for all images. Images are representative of three independent 
experiments. Blue=DAPI, red=AuNF. Scale bar=25µm.  
 
Figure 3. Transport of gold nanoflowers (AuNF) across BBB endothelial monolayers. hCMEC/D3 
(a) or primary brain endothelial cell (b) monolayers grown on transwell supports were treated with 
AuNF (10µg/mL) functionalized with 4-ethylcatecholamine (4-EC) or L-DOPA. Following a 48hr 
incubation period, AuNF transport across the monolayers was quantified by measuring gold content in 
the basolateral cell medium (basal Au) through ICP-AES. AuNF transport was calculated as percentage 
of the initial dose (%ID). Transport of L-DOPA-AuNF across primary brain endothelial monolayers 
grown on transwell supports was visualized (24hr) through high-resolution TEM (c). Images revealed 
AuNF closely interacted with the apical cell membrane (top panel, dashed arrow). In addition, AuNF 
were internalized into the intracellular space (bottom panel, solid arrow), as well as exiting into the 
basolateral space (bottom panel, arrow head), demonstrating successful transcytosis of the AuNF. 
Results in are displayed as mean+SEM of five (a) or three (b) independent experiments. *denotes 
p<0.05 as determined by a StudentÕs t-test. Images are representative of two independent monolayers.   
Figure 4. Internalization of gold nanoflowers (AuNF) into brain macrophages (microglia). 
Microglia cells (N9 cell line) were treated with 10µg/mL AuNF functionalized with either 4-
ethylcatecholamine (4-EC), dopamine (DA), L-DOPA or D-DOPA. AuNF cellular internalization (a) 
and AuNF remaining in the culture medium (b) 24hr following treatment were calculated by quantifying 
gold through ICP-AES. AuNF quantity was calculated as a percentage of the initial dose (%ID). Results 
are displayed as mean+SEM of at least three independent experiments. ***denotes p<0.001, vs. 4-EC. 
###denotes p<0. 0.001 vs. DA. Statistical significance was determined by a one-way ANOVA with 
TukeyÕs post-hoc test.  
 
Figure 5. Light transmission and confocal reflectance microscopy imaging of intracellular gold 
nanoflowers (AuNF) in brain macrophage (microglia) cells. Internalization of AuNF into microglia 
cells (N9 cell line) following a 24hr treatment (10µg/mL) was visualized through light transmission 
microscopy (a-c) and confocal reflectance imaging (d-f) employing an argon 546 nm laser. To visualize 
the cell bodies, microglia were stained with an anti-b-actin antibody. Laser power, exposure and gain 
parameters were kept constant for all images. Images are representative of three independent 
experiments. Blue=DAPI, red=b-actin immunofluorescence, yellow=AuNF. Scale bar=55µm (top 
panels) or 25µm (bottom panels). 
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